PMID- 11997282
OWN - NLM
STAT- MEDLINE
DCOM- 20020516
LR  - 20190623
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 105
IP  - 16
DP  - 2002 Apr 23
TI  - Human leukocyte antigen-G expression after heart transplantation is associated 
      with a reduced incidence of rejection.
PG  - 1949-54
AB  - BACKGROUND: Human leukocyte antigen (HLA)-G, a nonclassic major 
      histocompatibility complex class I molecule expressed in the extravillous 
      cytotrophoblast at the feto-maternal interface, is known to protect the fetus 
      from maternal cellular immunity. In a preliminary study, we showed that HLA-G is 
      expressed in the hearts of some patients after heart transplantation. METHODS AND 
      RESULTS: In the present study, a larger number of patients was investigated to 
      confirm this finding and to look for possible correlations between HLA-G 
      expression and the number and types of rejection. Expression of HLA-G in 
      endomyocardial biopsy specimens was investigated by immunohistochemical analysis, 
      and detection of the soluble HLA-G in the serum was performed by 
      immunoprecipitation followed by Western blot analysis. HLA-G was detected in the 
      biopsy specimens and serum of 9 of 51 patients (18%). The number of episodes of 
      acute rejection was significantly lower in HLA-G-positive patients (1.2+/-1.1) as 
      compared with HLA-G-negative patients (4.5+/-2.8) (P<0.001). No chronic rejection 
      was observed in HLA-G-positive patients, whereas 15 HLA-G-negative patients had 
      chronic rejection (P<0.032). A longitudinal study of these patients reveals that 
      the status of HLA-G expression was maintained after 6 months both in serum and in 
      biopsy specimens. During this period, HLA-G-positive patients did not have 
      chronic rejection. CONCLUSIONS: There is a significant correlation between 
      rejection and HLA-G expression in the heart after transplantation. HLA-G 
      expression and its effect in reducing the incidence and severity of rejection 
      seem to be stable throughout the evolution.
FAU - Lila, Nermine
AU  - Lila N
AD  - Laboratory for the Study of Cardiac Grafts and Prostheses, University of Pierre 
      et Marie Curie, Broussais Hospital, Paris, France. nerminelila@yahoo.fr
FAU - Amrein, Catherine
AU  - Amrein C
FAU - Guillemain, Romain
AU  - Guillemain R
FAU - Chevalier, Patrick
AU  - Chevalier P
FAU - Latremouille, Christian
AU  - Latremouille C
FAU - Fabiani, Jean-Noel
AU  - Fabiani JN
FAU - Dausset, Jean
AU  - Dausset J
FAU - Carosella, Edgardo D
AU  - Carosella ED
FAU - Carpentier, Alain
AU  - Carpentier A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Endocardium/metabolism
MH  - Female
MH  - Graft Rejection/diagnosis/epidemiology/*metabolism
MH  - HLA Antigens/*metabolism
MH  - HLA-G Antigens
MH  - *Heart Transplantation
MH  - Histocompatibility
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Humans
MH  - Incidence
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
EDAT- 2002/05/09 10:00
MHDA- 2002/05/17 10:01
CRDT- 2002/05/09 10:00
PHST- 2002/05/09 10:00 [pubmed]
PHST- 2002/05/17 10:01 [medline]
PHST- 2002/05/09 10:00 [entrez]
AID - 10.1161/01.cir.0000015075.89984.46 [doi]
PST - ppublish
SO  - Circulation. 2002 Apr 23;105(16):1949-54. doi: 
      10.1161/01.cir.0000015075.89984.46.